Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache [RETIRED]
Geisinger Health System · Rush University Medical Center · +9 more institutions
Abstract
To update the 2008 American Academy of Neurology (AAN) guidelines regarding botulinum neurotoxin for blepharospasm, cervical dystonia (CD), headache, and adult spasticity.
We searched the literature for relevant articles and classified them using 2004 AAN criteria. RESULTS AND RECOMMENDATIONS: Blepharospasm: OnabotulinumtoxinA (onaBoNT-A) and incobotulinumtoxinA (incoBoNT-A) are probably effective and should be considered (Level B). AbobotulinumtoxinA (aboBoNT-A) is possibly effective and may be considered (Level C). CD: AboBoNT-A and rimabotulinumtoxinB (rimaBoNT-B) are established as effective and should be offered (Level A), and onaBoNT-A and incoBoNT-A are probably effective and should be considered (Level B). Adult spasticity: AboBoNT-A, incoBoNT-A, and onaBoNT-A are established as effective and should be offered (Level A), and rimaBoNT-B is probably effective and should be considered (Level B), for upper limb spasticity. AboBoNT-A and onaBoNT-A are established as effective and should be offered (Level A) for lower-limb spasticity. Headache: OnaBoNT-A is established as effective and should be offered to increase headache-free days (Level A) and is probably effective and should be considered to improve health-related quality of life (Level B) in chronic migraine. OnaBoNT-A is established as ineffective and should not be offered for episodic migraine (Level A) and is probably ineffective for chronic tension-type headaches (Level B).
Citation impact
- FWCI
- 39.62
- Percentile
- 100%
- References
- 41
Authors
14- DMDavid M. SimpsonCorresponding
Geisinger Health System, Rush University Medical Center, Kaiser Permanente, Bronson Methodist Hospital, University of Maryland, Baltimore, University of Kansas, University Hospital Augsburg, Los Angeles Medical Center, Baylor College of Medicine, Stanford University, Palo Alto University
- MHMark Hallett
Kaiser Permanente, Los Angeles Medical Center, Stanford University, Baylor College of Medicine, University Hospital Augsburg, Geisinger Health System, Palo Alto University, Rush University Medical Center, University of Maryland, Baltimore, University of Kansas, Bronson Methodist Hospital
- EAEric Ashman
University of Kansas, Rush University Medical Center, Stanford University, Bronson Methodist Hospital, University of Maryland, Baltimore, Geisinger Health System, Los Angeles Medical Center, University Hospital Augsburg, Kaiser Permanente, Palo Alto University, Baylor College of Medicine
- CCCynthia Comella
Rush University Medical Center, Stanford University, Los Angeles Medical Center, Kaiser Permanente, Geisinger Health System, University of Kansas, Palo Alto University, Bronson Methodist Hospital, University Hospital Augsburg, University of Maryland, Baltimore, Baylor College of Medicine
- MWMark W. Green
Stanford University, University of Kansas, University Hospital Augsburg, Palo Alto University, Kaiser Permanente, Geisinger Health System, Los Angeles Medical Center, University of Maryland, Baltimore, Baylor College of Medicine, Bronson Methodist Hospital, Rush University Medical Center
Topics & keywords
- Blepharospasm
- Cervical dystonia
- Spasticity
- Medicine
- Botulinum toxin
- Dystonia
- Headaches
- Migraine